BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 10080613)

  • 1. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.
    Graziano SL; Gamble GP; Newman NB; Abbott LZ; Rooney M; Mookherjee S; Lamb ML; Kohman LJ; Poiesz BJ
    J Clin Oncol; 1999 Feb; 17(2):668-75. PubMed ID: 10080613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
    Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
    J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients.
    Rosell R; Li S; Skacel Z; Mate JL; Maestre J; Canela M; Tolosa E; Armengol P; Barnadas A; Ariza A
    Oncogene; 1993 Sep; 8(9):2407-12. PubMed ID: 8395679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. K-ras codon 12 mutations detected with enriched PCR method in operable non-small cell lung cancer.
    Kovalchuk O; Chyczewska E; Niklinska W; Niklinski J; Naumnik W; Chyczewski L
    Folia Histochem Cytobiol; 2001; 39 Suppl 2():68-9. PubMed ID: 11820632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
    Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
    Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?
    Camps C; Sirera R; Bremnes R; Blasco A; Sancho E; Bayo P; Safont MJ; Sánchez JJ; Tarón M; Rosell R
    Lung Cancer; 2005 Dec; 50(3):339-46. PubMed ID: 16139926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients.
    Hatzaki A; Razi E; Anagnostopoulou K; Iliadis K; Kodaxis A; Papaioannou D; Labropoulos S; Vasilaki M; Kosmidis P; Saetta A; Mihalatos M; Nasioulas G
    Mol Cell Probes; 2001 Oct; 15(5):243-7. PubMed ID: 11735295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
    Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
    Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women.
    Nelson HH; Christiani DC; Mark EJ; Wiencke JK; Wain JC; Kelsey KT
    J Natl Cancer Inst; 1999 Dec; 91(23):2032-8. PubMed ID: 10580029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of K-ras mutations in lung carcinomas: relationship to prognosis.
    Keohavong P; DeMichele MA; Melacrinos AC; Landreneau RJ; Weyant RJ; Siegfried JM
    Clin Cancer Res; 1996 Feb; 2(2):411-8. PubMed ID: 9816185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.
    Vatan O; Bilaloglu R; Tunca B; Cecener G; Gebitekin C; Egeli U; Yakut T; Urer N
    Tumori; 2007; 93(5):473-7. PubMed ID: 18038880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.
    Sarkar FH; Valdivieso M; Borders J; Yao KL; Raval MM; Madan SK; Sreepathi P; Shimoyama R; Steiger Z; Visscher DW
    Diagn Mol Pathol; 1995 Dec; 4(4):266-73. PubMed ID: 8634783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of activated K-ras in non-small cell lung cancer by membrane array: a comparison with direct sequencing.
    Chong IW; Chang MY; Sheu CC; Wang CY; Hwang JJ; Huang MS; Lin SR
    Oncol Rep; 2007 Jul; 18(1):17-24. PubMed ID: 17549340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. K-ras genotypes and prognosis in non-small-cell lung cancer.
    Rosell R; Monzo M; Molina F; Martinez E; Pifarre A; Moreno I; Mate JL; de Anta JM; Sanchez M; Font A
    Ann Oncol; 1995; 6 Suppl 3():S15-20. PubMed ID: 8616107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy.
    Broermann P; Junker K; Brandt BH; Heinecke A; Freitag L; Klinke F; Berdel WE; Thomas M
    Cancer; 2002 Apr; 94(7):2055-62. PubMed ID: 11932909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.
    Fukuyama Y; Mitsudomi T; Sugio K; Ishida T; Akazawa K; Sugimachi K
    Br J Cancer; 1997; 75(8):1125-30. PubMed ID: 9099959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma.
    Li S; Rosell R; Urban A; Font A; Ariza A; Armengol P; Abad A; Navas JJ; Monzo M
    Lung Cancer; 1994 Jul; 11(1-2):19-27. PubMed ID: 8081702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.